Jul. 2 at 5:17 PM
$BCLI In an AI + quantum era, exosome platforms become the delivery infrastructure for CNS therapeutics.
If BrainStorm’s platform evolves into:
a BBB‑capable exosome system
a payload‑flexible exosome carrier
a scalable CNS delivery layer
…it could be worth:
$20B–
$40B (realistic strategic value)
and
$100B+ (if exosomes become the CNS delivery standard)
Not as a company,
but as a platform — the same way LNPs and mRNA became trillion‑dollar infrastructure.